SPRO, ABBV Secure FDA Approvals; NMRA Halts Trial; BIIB Acquires RayThera

Spero Therapeutics (SPRO) and AbbVie (ABBV) recently received U.S. FDA approvals for new therapies, while Neumora Therapeutics (NMRA) halted a significant clinical trial. SPRO's oral antibiotic, Tebipenem HBr, secured approval for complicated urinary tract infections (cUTI) in patients with limited treatment options. AbbVie's Epkinly gained approval for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Conversely, Neumora Therapeutics (NMRA) ceased its KOASTAL-1 Phase 2 trial for navacaprant (NMRA-140) in major depressive disorder (MDD) following a futility analysis. In other corporate news, Biogen (BIIB) acquired private company RayThera for $16.25 million upfront, plus potential milestones up to $112.5 million, to advance RT-140 for amyotrophic lateral sclerosis (ALS). EngageSmart (ENGN) announced a 10% workforce reduction, anticipating $10-$12 million in charges in Q2 2026.